Skip to main content
SpringerLink
Log in

Update on the treatment of hepatocellular carcinoma

  • Special article
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Hepatocellular carcinoma (HCC), the fifth leading cause of cancer death worldwide, is a tumour with dismal prognosis [1]. In recent years, significant advances have been made and survival of patients with HCC has been prolonged and even cure can be achieved in a sizeable number of patients. The biggest advances are viable through screening and surveillance programmes of the population at risk, which includes all patients with cirrhosis of the liver and patients chronically infected with hepatitis B virus. Through regular ultrasound screening at 6-month intervals, detection rates and through this treatment and survival have been improved dramatically [2]. Through these surveillance programmes, at least 80% of the patients with HCC in western countries will undergo treatment for HCC of any kind with proven efficacy on survival. Only about 20% of patients with endstage tumours at the time of diagnosis will have no other option left than supportive care [3].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut, 48: 103–109, 2001

    Article  PubMed  CAS  Google Scholar 

  • Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology, 126: 1005–1014, 2004

    Article  PubMed  Google Scholar 

  • Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology, 127: S179–S188, 2004

    Article  PubMed  CAS  Google Scholar 

  • Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet, 362: 1907–1917, 2003

    Article  PubMed  Google Scholar 

  • Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19: 329–338, 1999

    Article  PubMed  CAS  Google Scholar 

  • Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia Pagan JC, Visa J, Bru C, Rodés J. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology, 111: 1018–1022, 1996

    Article  PubMed  CAS  Google Scholar 

  • Forner A, Bruix J. Locoregional treatment for hepatocellular carcinoma: from clinical exploration to robust clinical data, changing standards of care. Hepatology, 47: 5–7, 2008

    Article  PubMed  Google Scholar 

  • Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology, 47: 82–89, 2008

    Article  PubMed  Google Scholar 

  • Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis [see comments]. N Engl J Med, 334: 693–699, 1996

    Article  PubMed  CAS  Google Scholar 

  • Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis, 25: 181–200, 2005

    Article  PubMed  Google Scholar 

  • Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, Margreiter R, Vogel W. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl, 13: 272–279, 2007

    Article  PubMed  Google Scholar 

  • Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, Rodes J, Bruix J. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut, 50: 123–128, 2002

    Article  PubMed  CAS  Google Scholar 

  • Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, Quan D, McAllister V, Ghent C, Levstik M, McLean C, Chakrabarti S, Garcia B, Driman DK. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl, 13: 543–551, 2007

    Article  PubMed  Google Scholar 

  • Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology, 127: S268–S276, 2004

    Article  PubMed  Google Scholar 

  • Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant, 7: 2587–2596, 2007

    Article  PubMed  CAS  Google Scholar 

  • Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl, 8: 765–774, 2002

    Article  PubMed  Google Scholar 

  • Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, Pompili M, Brunello F, Lazzaroni S, Torzilli G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology, 197: 101–108, 1995

    PubMed  CAS  Google Scholar 

  • Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology, 210: 655–661, 1999

    PubMed  CAS  Google Scholar 

  • Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology, 129: 122–130, 2005

    Article  PubMed  Google Scholar 

  • Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut, 54: 1151–1156, 2005

    Article  PubMed  CAS  Google Scholar 

  • Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm. Gastroenterology, 127: 1714–1723, 2004

    Article  PubMed  Google Scholar 

  • Livraghi T, Lazzaroni S, Meloni F. Radiofrequency thermal ablation of hepatocellular carcinoma. Eur J Ultrasound, 13: 159–166, 2001

    Article  PubMed  CAS  Google Scholar 

  • Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg, 243: 321–328, 2006

    Article  PubMed  Google Scholar 

  • Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology, 37: 429–442, 2003

    Article  PubMed  CAS  Google Scholar 

  • Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell, 5: 215–219, 2004

    Article  PubMed  CAS  Google Scholar 

  • Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme) [see comments]. Lancet, 352: 17–20, 1998

  • Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology, 45: 9–15, 2007

    Article  PubMed  CAS  Google Scholar 

  • Pinter M, Wichlas M, Schmid K, Plank C, Müller C, Wrba F, Peck-Radosavljevic M. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur J Gastroenterol Hepatol, in press, 2008

  • Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol, 23: 6657–6663, 2005

    Article  PubMed  CAS  Google Scholar 

  • Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 24: 4293–4300, 2006

    Article  PubMed  CAS  Google Scholar 

  • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol, 25: 962s (LBA1), 2007

    Google Scholar 

  • Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovici M, Ricci S. Is sorafinib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol, 26 (Suppl): A140, 2008

    Google Scholar 

  • Pinter MW, Sieghart W, Graziadei I, Königsberg R, Peck-Radosavljevic M. Sorafenib in multifocal hepatocellular carcinoma and advanced liver dysfunction. Hepatology, 46 (Suppl 1): A383, 2007

    Google Scholar 

  • Faivre SJ, Raymond E, Douillard J, Boucher E, Lim HY, Kim JS, Lanzalone S, Lechuga MJ, Sherman L, Cheng AL. Phase II trial investigating the efficacy and safety of sunitinib in patients with unresectable hepatocellular carcinoma (HCC). Eur J Cancer Suppl, 5: 270, 2007

    Article  Google Scholar 

  • Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer, 110: 581–589, 2007

    Article  PubMed  CAS  Google Scholar 

  • Abou-Alfa G, Johnson P, Knox J, Davidenko I, Lacava J, Leung T, Mori AL, Leberre M-A, Voliotis DS, Saltz L. Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur J Cancer, (Suppl 5): 259, 2007

Download references

Author information

Authors and Affiliations

  1. Klinische Abteilung Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin III, Wien, Austria

    M. Peck-Radosavljevic

Authors
  1. M. Peck-Radosavljevic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Peck-Radosavljevic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peck-Radosavljevic, M. Update on the treatment of hepatocellular carcinoma. memo 1, 111–115 (2008). https://doi.org/10.1007/s12254-008-0018-1

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-008-0018-1

Keywords

Search

Navigation